Saijo Nagahiro, Kenmotsu Hirotsugu
Kinki University School of Medicine, Osaka.
Intern Med. 2010;49(18):1923-34. doi: 10.2169/internalmedicine.49.3845. Epub 2010 Sep 15.
Numerous molecular target drugs have been introduced for the treatment of advanced malignancies. In the treatment of lung cancer, epidermoid growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) demonstrate striking antitumor activity in selected EGFR mutation positive patients. Patient selection by biomarker is extremely important to obtain successful results. The anti-vascular endothelial growth factor (VEGF) antibody, bevacizumab, shows a markedly increased response rate, progression free survival of advanced non-squamous cell lung cancer when combined with cytotoxic drugs. The classification of lung cancer is rapidly changing based on the advances in molecular biology. Here, the recent development of new molecular target drugs against lung cancer is thoroughly reviewed in addition to EGFR-TKIs and bevacizumab with special emphasis on the clinical application.
许多分子靶向药物已被用于治疗晚期恶性肿瘤。在肺癌治疗中，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）在特定的EGFR突变阳性患者中显示出显著的抗肿瘤活性。通过生物标志物进行患者选择对于获得成功结果极为重要。抗血管内皮生长因子（VEGF）抗体贝伐单抗与细胞毒性药物联合使用时，晚期非鳞状细胞肺癌的缓解率和无进展生存期显著提高。基于分子生物学的进展，肺癌的分类正在迅速变化。在此，除了EGFR-TKI和贝伐单抗外，还对近期针对肺癌的新型分子靶向药物的发展进行了全面综述，并特别强调了其临床应用。
